Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
WILMINGTON, Del., Feb. 19, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)?
- Did you purchase your shares between May 17, 2013 and December 28, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Anavex between May 17, 2013 and December 28, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than February 29, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Anavex during the Class Period, or purchased shares prior to the Class Period and still hold Anavex, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/anavex-life-sciences-corp-avxl.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
